Cyclophosphamide
Pediatric Solid Tumor
Robbie MajznerSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Pediatric Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pegteograstim Samsung Medical Center | Phase 2 | CCC |
Carboplatin The Korean Society of Pediatric Hematology Oncology | Phase 2 | CCC |
Irinotecan St. Jude Children's Research Hospital | Phase 1/2 | CCC |
(+)-VINCRISTINE St. Jude Children's Research Hospital | Phase 1/2 | CCC |
RH-ARG1-PEG-5,000 MW University of Birmingham | Phase 1/2 | CCC |
View all 26 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →